Evaluation of Serum Endocan Level and Erectile Functions in Patients with Psoriasis | ||||
| Benha Journal of Applied Sciences | ||||
| Article 7, Volume 9, Issue 2, February 2024, Page 61-67 PDF (568.22 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2024.274770.1348 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Fatma Mohammed El Esawy1; Ghada Mohamed Abd El Khalik2; Amira Osama Abd EL-Ghafar3; Shaimaa Muhammed shalaby  4
| ||||
| 1Professor of Dermatology, Venereology and Andrology Faculty of Medicine - Benha University | ||||
| 2Lecturer of Dermatology, Venerology and Andrology Faculty of Medicine - Benha University | ||||
| 3Lecturer of Clinical and Chemical pathology Faculty of Medicine - Benha University | ||||
| 4Master Degree in Dermatology, Venereology & Andrology | ||||
| Abstract | ||||
| Background: In psoriasis patients, circulating endocan is associated with disease severity and cardiovascular risk. Once again, endocan levels were correlated with inflammatory markers; individuals with psoriasis had greater amounts than controls. Elevated endocan levels may indicate inflammatory and endothelial factors contributing to erectile dysfunction pathophysiology (ED). As a new diagnostic indicator for the degree of erectile dysfunction, endocan could be helpful. The purpose of this review is to examine erectile dysfunction, serum endocan levels, psoriasis epidemiology, and pathophysiology in great detail. The endothelial and inflammatory components of the aetiology of both psoriasis and erectile dysfunction may be represented by increased endocan levels, according to the conclusions. One possible use for endocan is as a diagnostic marker for erectile dysfunction and psoriasis. | ||||
| Keywords | ||||
| Erectile Functions; Endocan; and Psoriasis are the main terms here | ||||
|
Statistics Article View: 9 PDF Download: 79 |
||||
